Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (141-150 of 236) with videos related to

Pageof 24
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancerJerome D Winegarden, Ann M Mauer, Thomas F Gajewski, et al.
Molecular Cancer Therapeutics|August 12, 2018
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix AffinityJun Ishihara, Ako Ishihara, Lambert Potin, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanomaJonathan A Trujillo, Jason J Luke, Yuanyuan Zha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2016
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor RejectionCésar Evaristo, Stefani Spranger, Sarah E Barnes, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanomaStefani Spranger, Jason J Luke, Riyue Bao, et al.
Immunity|December 14, 2002
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cellsMichael T Spiotto, Ping Yu, Donald A Rowley, et al.
Journal of Translational Medicine|December 12, 2012
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)Thomas F Gajewski, April K S Salama, Donna Niedzwiecki, et al.
Melanoma Research|May 11, 2017
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanomaAhmad A Tarhini, Stergios J Moschos, Yan Lin, et al.
International Journal of Cancer|February 17, 2006
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitroChristian Blank, Juergen Kuball, Simon Voelkl, et al.
Journal of Magnetic Resonance Imaging : JMRI|June 29, 2004
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over timeMilica Medved, Greg Karczmar, Cheng Yang, et al.
Pageof 24

Showing results (141-150 of 236) with videos related to

Sort By:
Pageof 24
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancerJerome D Winegarden, Ann M Mauer, Thomas F Gajewski, et al.
Molecular Cancer Therapeutics|August 12, 2018
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix AffinityJun Ishihara, Ako Ishihara, Lambert Potin, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanomaJonathan A Trujillo, Jason J Luke, Yuanyuan Zha, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2016
Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor RejectionCésar Evaristo, Stefani Spranger, Sarah E Barnes, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanomaStefani Spranger, Jason J Luke, Riyue Bao, et al.
Immunity|December 14, 2002
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cellsMichael T Spiotto, Ping Yu, Donald A Rowley, et al.
Journal of Translational Medicine|December 12, 2012
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)Thomas F Gajewski, April K S Salama, Donna Niedzwiecki, et al.
Melanoma Research|May 11, 2017
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanomaAhmad A Tarhini, Stergios J Moschos, Yan Lin, et al.
International Journal of Cancer|February 17, 2006
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitroChristian Blank, Juergen Kuball, Simon Voelkl, et al.
Journal of Magnetic Resonance Imaging : JMRI|June 29, 2004
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over timeMilica Medved, Greg Karczmar, Cheng Yang, et al.
Pageof 24